Voxdale joins MIRA: Advancing Sustainable Diagnostics for Cervical Cancer Screening
•
2 min read
Project overview
Cervical cancer remains a global health concern, with roughly 75 % of cases linked to persistent high‑risk HPV infections.
Although vaccines exist, their effectiveness depends on timely administration and broad uptake—conditions that are far from universal. The result is a pressing need for fast, dependable testing that can guide vaccination strategies and encourage early detection.
MIRA aims to bridge that gap. The project is developing a compact diagnostic device that simplifies the entire workflow—from sample collection to clear, on‑the‑spot results—while operating independently of traditional lab infrastructure. Just as important, the single‑use test cartridge will be produced from renewable materials and designed for full composability, setting a new benchmark for eco‑conscious medical technology.
Project overview
Cervical cancer remains a global health concern, with roughly 75 % of cases linked to persistent high‑risk HPV infections.
Although vaccines exist, their effectiveness depends on timely administration and broad uptake—conditions that are far from universal. The result is a pressing need for fast, dependable testing that can guide vaccination strategies and encourage early detection.
MIRA aims to bridge that gap. The project is developing a compact diagnostic device that simplifies the entire workflow—from sample collection to clear, on‑the‑spot results—while operating independently of traditional lab infrastructure. Just as important, the single‑use test cartridge will be produced from renewable materials and designed for full composability, setting a new benchmark for eco‑conscious medical technology.
Project overview
Cervical cancer remains a global health concern, with roughly 75 % of cases linked to persistent high‑risk HPV infections.
Although vaccines exist, their effectiveness depends on timely administration and broad uptake—conditions that are far from universal. The result is a pressing need for fast, dependable testing that can guide vaccination strategies and encourage early detection.
MIRA aims to bridge that gap. The project is developing a compact diagnostic device that simplifies the entire workflow—from sample collection to clear, on‑the‑spot results—while operating independently of traditional lab infrastructure. Just as important, the single‑use test cartridge will be produced from renewable materials and designed for full composability, setting a new benchmark for eco‑conscious medical technology.
Voxdale’s contribution
As MIRA’s design‑engineering partner, Voxdale is translating the consortium’s molecular science into a manufacturable, clinician‑friendly product. Our team is focusing on:
User‑centred hardware development – ensuring the device is intuitive for clinicians and adaptable to diverse care settings.
Industrialisation readiness – aligning the design with high‑volume manufacturing processes from the outset.
Voxdale’s contribution
Voxdale’s contribution
Project partners
INTU Diagnostics GmbH – project coordination
Fraunhofer IZI – molecular‑diagnostic and sample‑processing expertise
Leipzig University Hospital (Gynecology Clinic) – clinical partner providing patient samples and medical insight
Institut für Molekulare Diagnostik und Bioanalytik (IMDB) gGmbH – additional molecular‑diagnostics support
Together, we’re shaping a diagnostic platform that is not only effective but also aligned with the healthcare sector’s growing commitment to sustainability.
Project partners
Project partners
Continue reading
Continue reading
Wonderful ideas, engineered from sketch to scale
Wonderful ideas, engineered from sketch to scale
Wonderful ideas, engineered from sketch to scale
Wonderful ideas, engineered from sketch to scale
© 2026 Voxdale BV
© 2026 Voxdale BV
© 2026 Voxdale BV